CN1382490A - 选择性pde10抑制物的治疗用途 - Google Patents

选择性pde10抑制物的治疗用途 Download PDF

Info

Publication number
CN1382490A
CN1382490A CN02118061A CN02118061A CN1382490A CN 1382490 A CN1382490 A CN 1382490A CN 02118061 A CN02118061 A CN 02118061A CN 02118061 A CN02118061 A CN 02118061A CN 1382490 A CN1382490 A CN 1382490A
Authority
CN
China
Prior art keywords
disorder
disease
pde10
episodes
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN02118061A
Other languages
English (en)
Chinese (zh)
Inventor
洛兰·A·莱博尔
弗兰克·S·门尼蒂
克里斯托弗·J·施米特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23092939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1382490(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1382490A publication Critical patent/CN1382490A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN02118061A 2001-04-20 2002-04-22 选择性pde10抑制物的治疗用途 Pending CN1382490A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28514801P 2001-04-20 2001-04-20
US60/285,148 2001-04-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006100045277A Division CN1840181A (zh) 2001-04-20 2002-04-22 选择性pde10抑制物的治疗用途

Publications (1)

Publication Number Publication Date
CN1382490A true CN1382490A (zh) 2002-12-04

Family

ID=23092939

Family Applications (2)

Application Number Title Priority Date Filing Date
CN02118061A Pending CN1382490A (zh) 2001-04-20 2002-04-22 选择性pde10抑制物的治疗用途
CNA2006100045277A Pending CN1840181A (zh) 2001-04-20 2002-04-22 选择性pde10抑制物的治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006100045277A Pending CN1840181A (zh) 2001-04-20 2002-04-22 选择性pde10抑制物的治疗用途

Country Status (13)

Country Link
US (1) US20030008806A1 (enExample)
EP (1) EP1250923A3 (enExample)
JP (1) JP3839343B2 (enExample)
KR (2) KR20020082136A (enExample)
CN (2) CN1382490A (enExample)
AU (1) AU3440902A (enExample)
CA (1) CA2382326A1 (enExample)
HK (1) HK1048070A1 (enExample)
HU (1) HUP0201310A3 (enExample)
IL (1) IL149106A0 (enExample)
NZ (1) NZ518478A (enExample)
PL (1) PL353535A1 (enExample)
ZA (1) ZA200203123B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2004042391A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
AU2003291418A1 (en) * 2002-11-15 2004-06-15 Merck And Co., Inc. Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
TW200510407A (en) * 2003-06-30 2005-03-16 Altana Pharma Ag Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
ATE438398T1 (de) * 2003-06-30 2009-08-15 Nycomed Gmbh Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
ES2326337T3 (es) * 2005-01-12 2009-10-07 Nycomed Gmbh Nuevas pirrolodihidroisoquinolinas como inhibidores de pde10.
AU2006279548A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2661850A1 (en) * 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
WO2008029829A1 (en) 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
WO2010035745A1 (ja) 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2010041711A1 (ja) 2008-10-09 2010-04-15 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
EP2539342B1 (en) 2010-02-26 2015-04-15 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as pde10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP2963037B1 (en) 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
WO2015006689A1 (en) * 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
JP3276762B2 (ja) * 1993-12-28 2002-04-22 日本臓器製薬株式会社 イソキノリン誘導体を含有する医薬組成物
HUT71408A (en) * 1994-01-14 1995-11-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
CA2187086A1 (en) * 1994-04-15 1995-10-26 Masaomi Iyo A pharmaceutical composition for therapeutically treating tardive dyskinesia and uses therof
AU2252297A (en) * 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
KR0177295B1 (ko) * 1996-02-28 1999-03-20 정명식 이소퀴놀린 화합물을 함유하는 항우울제
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
ATE331791T1 (de) * 1998-02-23 2006-07-15 Icos Corp Phosphodiesterase 10
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same

Also Published As

Publication number Publication date
IL149106A0 (en) 2002-11-10
HU0201310D0 (enExample) 2002-06-29
AU3440902A (en) 2002-10-24
CA2382326A1 (en) 2002-10-20
US20030008806A1 (en) 2003-01-09
HK1048070A1 (zh) 2003-03-21
PL353535A1 (en) 2002-10-21
EP1250923A3 (en) 2003-01-15
KR20020082136A (ko) 2002-10-30
ZA200203123B (en) 2003-10-20
JP2002363103A (ja) 2002-12-18
JP3839343B2 (ja) 2006-11-01
CN1840181A (zh) 2006-10-04
KR20060002003A (ko) 2006-01-06
HUP0201310A2 (hu) 2003-02-28
EP1250923A2 (en) 2002-10-23
NZ518478A (en) 2004-04-30
HUP0201310A3 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
CN1382490A (zh) 选择性pde10抑制物的治疗用途
RU2303259C2 (ru) Терапевтическое применение селективных ингибиторов pde10
Li et al. Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia
Ma et al. A breakdown of metabolic reprogramming in microglia induced by CKLF1 exacerbates immune tolerance in ischemic stroke
J. Titus et al. Phosphodiesterase inhibitors as therapeutics for traumatic brain injury
Vidal et al. Decreasing the expression of GABAA α5 subunit-containing receptors partially improves cognitive, electrophysiological, and morphological hippocampal defects in the Ts65Dn model of Down syndrome
Wakasugi et al. A rare olive compound oleacein functions as a TrkB agonist and mitigates neuroinflammation both in vitro and in vivo
US20030018047A1 (en) Therapeutic use of selective PDE10 inhibitors
Zhang et al. CXC chemokine receptor type 7 antibody enhances neural plasticity after ischemic stroke
Gross-Isseroff et al. Unaltered α2-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis
EP1666886A2 (en) Method of identifying selective PDE10 inhibitor compounds
HK1091746A (en) Therapeutic use of selective pde10 inhibitors
AU2007200574A1 (en) Therapeutic use of selective PDE10 inhibitors
HK1077331A (en) Therapeutic use of selective pde10 inhibitors
ZA200407823B (en) Therapeutic use of selective PDE10 inhibitors
Seraphin et al. Early life stress of maternal deprivation and peer-rearing jeopardize mesoprefrontal and mesolimbic dopamine receptors in the rhesus monkey
Aubry et al. Chronic treatment with amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala
Zhang Neuropsychopharmacological Effects of Selective Inhibitors of Subtypes of Phosphodiesterase-4 in Mice
Chen et al. Antidepressant Drugs and Phosphodiesterases
Laprairie et al. Alterations in expression and function of phosphodiesterases in Huntington’s disease
Herrera Genetic Variant BDNF (Val66Met) Polymorphism Alters Anxiety-Related Behavior
Wongwitdecha et al. Early isolation increase the antiimmobility effect of paroxetine in the mice forced swimming test
Sauvage et al. Autoradiographic distribution of [3H]-befloxatone, a selective and reversible MAO-A inhibitor in the rat brain
Lucca et al. Effects of an antidepressant treatment on S-adenosylmethlonine plasma levels
Bergqvist et al. Citalopram and release of brain 5-HT in experimental chronic hepatic encephalopathy

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1048070

Country of ref document: HK